| Dr Douglas R King, | |
|
1519 3rd St Se, Ste 230, Puyallup, WA 98372-3742 | |
| (253) 841-9640 | |
| (253) 841-7645 |
| Full Name | Dr Douglas R King |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 40 Years |
| Location | 1519 3rd St Se, Puyallup, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184643611 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD00023020 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Multicare Good Samaritan Hospital | Puyallup, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Multicare Health System | 7719899897 | 1704 |
News Archive
"It happened quietly, and it didn't make any headlines, but an agreement reached in Geneva last week represents a key step forward in the battle against some of the world's biggest killers: non-communicable diseases (NCDs), including heart disease, cancer, and diabetes," Ambassador Betty King, permanent representative of the United States to the U.N., writes in the U.S. Department of State's "DipNote" blog.
Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.
PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection.
A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.
› Verified 4 days ago
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
"It happened quietly, and it didn't make any headlines, but an agreement reached in Geneva last week represents a key step forward in the battle against some of the world's biggest killers: non-communicable diseases (NCDs), including heart disease, cancer, and diabetes," Ambassador Betty King, permanent representative of the United States to the U.N., writes in the U.S. Department of State's "DipNote" blog.
Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.
PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection.
A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.
› Verified 4 days ago
| Entity Name | Proliance Surgeons Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
"It happened quietly, and it didn't make any headlines, but an agreement reached in Geneva last week represents a key step forward in the battle against some of the world's biggest killers: non-communicable diseases (NCDs), including heart disease, cancer, and diabetes," Ambassador Betty King, permanent representative of the United States to the U.N., writes in the U.S. Department of State's "DipNote" blog.
Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.
PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection.
A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas R King, 805 Madison St, Suite 901, Seattle, WA 98104-1172 Ph: (206) 264-8100 | Dr Douglas R King, 1519 3rd St Se, Ste 230, Puyallup, WA 98372-3742 Ph: (253) 841-9640 |
News Archive
"It happened quietly, and it didn't make any headlines, but an agreement reached in Geneva last week represents a key step forward in the battle against some of the world's biggest killers: non-communicable diseases (NCDs), including heart disease, cancer, and diabetes," Ambassador Betty King, permanent representative of the United States to the U.N., writes in the U.S. Department of State's "DipNote" blog.
Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.
PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection.
A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.
› Verified 4 days ago
Dr. Cholwoo Anthony Kim, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1519 3rd St Se, Ste 230, Puyallup, WA 98372 Phone: 253-841-9640 Fax: 253-841-7645 | |
Dr. Kenneth A. Feucht, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1519 3rd St Se, Ste 230, Puyallup, WA 98372 Phone: 253-445-1844 Fax: 253-841-9701 | |
Brian Nelson, Surgery Medicare: Accepting Medicare Assignments Practice Location: 208 17th Ave Se, Puyallup, WA 98372 Phone: 253-840-1999 | |
Dr. Chia J. Chung, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 105 27th Ave Se, Puyallup, WA 98374 Phone: 253-848-8110 Fax: 253-845-3561 | |
Miles Mcbride Dale, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1519 3rd St Se Ste 230, Puyallup, WA 98372 Phone: 253-841-9640 Fax: 253-841-7645 | |
Robert Charles Wright, MD FACS Surgery Medicare: Accepting Medicare Assignments Practice Location: 208 17th Ave Se, Suite 201, Puyallup, WA 98372 Phone: 253-840-1999 Fax: 253-445-4125 |